A Serum Protein Signature Associated with Outcome …cancerimmunolres.aacrjournals.org/content/canimm/early/2017/12/05/...machine learning, predicted survival in patients receiving
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
A Serum Protein Signature Associated with Outcome After Anti-PD1 Therapy in Metastatic Melanoma
Mario Sznol2, Ryan J. Sullivan3, Shauna Blackmon3, Genevieve Boland3, Harriet M. Kluger2, Ruth
Halaban2, Antonella Bacchiocchi2, Paolo A. Ascierto4, Marilena Capone4, Carlos Oliveira5, Krista Meyer5,
Julia Grigorieva5, Senait G. Asmellash5, Joanna Roder5, Heinrich Roder5, and Jeffrey S. Weber1
From the 1Perlmutter Cancer Center, NYU-Langone Medical Center New York, NY: 2Smilow Cancer
Center, Yale University School of Medicine, New Haven, CT; 3Massachusetts General Hospital Cancer
Center, Boston, MA; 4 Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale”, Naples, Italy and 5Biodesix Inc, Boulder, CO
Running title: Serum protein signature for checkpoint protein inhibition
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
2. Ribas A, Puzanov I, Dummer R, et al: (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16 (8):908-918, 2015
3. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus Ipilimumab in Advanced
Melanoma. The New England Journal of Medicine 372 (26):2521-2532, 2015
4. Hodi FS, Kluger H, Sznol M, et al: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial Cancer Res 76, 2016 76 (suppl)
5. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus Docetaxel in Advanced Nonsquamous
Non-Small-Cell Lung Cancer. The New England Journal of medicine 373 (17):1627-1639, 2015
6. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of medicine 373 (2):123-135, 2015
7. Herbst RS, Baas P, Kim DW, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-
positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (10027):1540-1550, 2016
8. Herbst RS, Soria JC, Kowanetz M, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature 515 (7528):563-567, 2014
9. Daud AI, Wolchok JD, Robert C, et al Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. , 34(34):4102-4109, 2016
10. Ratcliffe MJ SA, Midha A, Barker C, et al A comparative study of PD-L1 diagnostic assays and the
classification of patients as PD-L1 positive and PD-L1 negative. Presented at the AACR Annual Meeting, New Orleans, LA, April 16—20 2016.
11. Taube JM, Anders RA, Young GD, et al Colocalization of inflammatory response with B7-h1
expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science Translational Medicine 4 (127):127ra137, 2012
12. Tumeh PC, Harview CL, Yearley JH, et al PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (7528):568-571, 2014
13. Daud AI, Wolchok JD, Robert C, et al Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. , 34(34):4102-4109, 2016
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
15. Sweis RF, Spranger S, Bao R, et al Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer immunology research 4 (7):563-568, 2016
16. Parsa AT, Waldron JS, Panner A, et al Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature medicine 13 (1):84-88, 2007
17. Gao J, Shi LZ, Zhao H, et al Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. ,167(2):397-404.e9, 2016
18. Hugo W, Zaretsky JM, Sun L, et al Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. , 165(1):35-44, 2016
19. Duncan MW, Asmellash S, Allen J, et al Extending the Information Content of the MALDI Analysis
of Biological Fluids (Deep MALDI). Presented at the ASMS, Minneapolis, MN, June 9 – 13, 2013
20. Roder H, Asmellash S, Allen J, et al, inventors; Biodesix Inc, assignee. Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof. United States patent US 9,279,798. 2016 March 8.
21. Roder, H, Roder, J, inventors; Biodesix Inc, assignee. Classification generation method using combination of mini-classifiers with regularization and uses thereof. United States patent US 9,477,906. 2016 October 25.
22. Weber JS, Kudchadkar RR, Yu B, et al Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. , 31(34):4311-8, 2013
23. Weber J, Gibney G, Kudchadkar R, et al Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab who had progressed after Ipilimumab. Cancer Immunol Res. , 4(4):345-53, 2016
24. Singal N, Kumar M, Kanaujia P K, et al MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front. Microbiol., 6: 791, 2015
25. Goodfellow I, Bengio Y, Courville A. Deep Learning, MIT Press (2017) Cambridge MA.
26. Breimann L. Bagging predictors. Machine Learning, 24:123-140, 1996.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
27. Weber J, Martinez, Roder H, et al Pre-treatment patient selection for nivolumab benefit based on serum mass spectra. Presented at SITC, National Harbor, MD, Nov 6 – 8 , 2015
28. Subramanian A, Tamayo P, Mootha VK, et al Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA, 102(43): 15545-50, 2005
29. Lavallee-Adam M, Rauniyar N, McClatchy D B, et al PSEA—Quant: A Protein Set Enrichment
Analysis on Label-Free and Label-Based Protein Quantification Data. J. Proteome Res. , 13: 5496-5509, 2014
30. Benjamini Y, Hochberg Y, Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Statist Soc B 57(1): 289-300, 1995
31. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer.
The New England Journal of Medicine. 2015;372:2018–28
32. Zhou J, Mahoney KM, Giobbie-Hurder A, et al Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res. 2017 Jun;5(6):480-492
33. Wu X, Giobbie-Hurder A, Liao X, et al Angiopoietin-2 as a Biomarker and Target for Immune
Checkpoint Therapy. Cancer Immunol Res. 2017 Jan;5(1):17-28
34. Larkin J, Chiarion-Sileni V, Gonzalez R, et al Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. , 373(1):23-34, 2015
35. Pierce BL, Ballard-Barbash R, Bernstein L, et al Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009, 27(21):3437-44, 2009
36. Mian S, Ugurel S, Parkinson E, et al Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol. , 23(22):5088-93, 2005
37. Findeisen P1, Zapatka M, Peccerella T, et al Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol. , 27(13):2199-208, 2009
38. Fang S, Wang Y, Sui D, Liu H, et al C-reactive protein as a marker of melanoma progression. J Clin Oncol. , 33(12):1389-96, 2015
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
39. Nakamura Y, Kitano S, Takahashi A, et al Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget. , doi: 10.18632/oncotarget.1267, 2015
40. Wang Y, Sun SN, Liu Q, et al Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. Cancer Discov. , 6(9):1022-35, 2016
41. Nabizadeh JA, Manthey HD, Steyn FJ, et al The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses. J Immunol. 196(11):4783-92, 2016
42. Bulla R, Tripodo C, Rami D, et al C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun. 7:10346. , 2016
43. Markiewski MM1, DeAngelis RA, Benencia F, et al Modulation of the antitumor immune
response by complement Nat Immunol. 2008 9(11):1225-35.
44. Antonio N, Bønnelykke-Behrndtz ML, Ward LC, et al The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. EMBO J. , 34(17):2219-36 , 2015
Figure legend
Figure 1: Kaplan-Meier plots of outcome data for all sets by classification groups sensitive and resistant.
Development results are shown in Figure 1a and 1b for OS and PFS, respectively. Figures 1c, 1d, 1e, 1f,
and 1g show the results of validations sets 1 through 5.
Tables:
Table 1: Patient characteristics of all sample sets
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Table 5. Proteins with significant univariate correlation (Mann-Whitney P < 0.05) with test classification in the PSEA reference sample set. All proteins showed relatively higher levels in the resistant group, unless marked with *, which were higher in the sensitive group.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412
Published OnlineFirst December 5, 2017.Cancer Immunol Res Mario Sznol, Ryan J. Sullivan, Shauna Blackmon, et al. Anti-PD1 Therapy in Metastatic MelanomaA Serum Protein Signature Associated with Outcome After
Updated version
10.1158/2326-6066.CIR-17-0412doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerimmunolres.aacrjournals.org/content/early/2017/12/05/2326-6066.CIR-17-0412To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 5, 2017; DOI: 10.1158/2326-6066.CIR-17-0412